Functional Endoscopic Sinus Surgery Market

Functional Endoscopic Sinus Surgery Market Size, Share & Trends

The size of global functional endoscopic sinus surgery market in terms of revenue was estimated to be worth $1.2 billion in 2024 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 7.6% from 2024 to 2029. The growth in this market is due to a significant shift towards minimally invasive, in-office surgery which is a more patient-friendly substitute. This has an added advantage over traditional procedures, for instance, less anaesthesia, more convenient, faster turn around times, and at reduced costs. Additionally, innovations in surgical techniques have emerged in MIS procedures like robotic-assisted surgeries which will offer improved precision and less tissue trauma. However, the shortage of skilled professionals and availability of non-surgical substitutes likely to restrain the market.

Functional Endoscopic Sinus Surgery Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Functional endoscopic sinus surgery Dynamics

DRIVER: High prevalence of chronic sinusitis

Sinusitis is a condition where the sinuses are inflamed for over twelve weeks. Chronic sinusitis can result from infections, nasal polyps, or sinus lining swelling. The American Academy of Allergy Asthma and Immunology (December 2023) states that about 20% of chronic rhinosinusitis (CRS) patients have nasal polyps. CRS is common, potentially affecting 1 in 8 people, and costs the US between USD 10-13 billion directly and over USD 20 billion indirectly each year.

RESTRAINT: Availability of non-surgical treatment

Chronic sinusitis causes inflammation of the nasal sinuses lasting 12 weeks or more and is one of the most common chronic conditions in the US. It's typically treated with medication, but surgery is needed for recurrent or persistent infections. Surgery is also considered for those with ongoing infections, abnormal sinus structures, or growths. As a result, nonsurgical treatments, such as medications to reduce inflammation and improve drainage, are widely popular.

OPPORTUNITY: Growing demand for organ transplants and cell & gene therapy

AI in sinus surgeries marks a major advancement in otolaryngology, promising more effective and safer procedures. Robotic-assisted technology has revolutionized functional endoscopic sinus surgery (FESS) by providing greater precision and control. Integrating robotic systems into surgeries enhances surgeons' skills, enabling intricate maneuvers with accuracy. These platforms offer improved visualization and magnification, allowing detailed examination and precise targeting of diseased tissue. The robotic arms, equipped with specialized instruments, offer superior range of motion and flexibility compared to traditional tools.

CHALLENGE: Storage and transportation logistics

Many countries currently face a shortage of skilled professionals to perform ENT procedures effectively. FESS requires specialized training and skills that are not widely available, leading to a scarcity of qualified surgeons. This shortage is especially pronounced in emerging markets, where access to FESS is limited. In 2023, the U.S. had over 12,000 otolaryngologists but is projected to face a shortage of 2,500 by 2025 (Source: Pubmed.gov). Some low-income countries have fewer than one ENT specialist per million people. Underdeveloped regions face this issue on a larger scale. For example, a 2020 PubMed survey of 22 African countries found that Zambia had only three expatriate ENT surgeons, and Malawi had none, relying on occasional visits from foreign ENT surgeons. In 2023, Zimbabwe, with over 15 million people, had only four ENT surgeons. The primary cause of this problem is the shortage of ENT health personnel.

Functional Endoscopic Sinus Surgery Ecosystem

Prominent companies in this market include well-established, financially stable manufacturers of Functional endoscopic sinus surgery. These companies have been operating in the market for several years and possess diversified state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include Medtronic plc (Ireland), Stryker Corporation (US), Olympus Corporation (Japan), B. Braun Melsungen Ag (Germany), and KARL STORZ (Germany).

In 2023, endoscopes segment to observe the highest growth rate of the functional endoscopic sinus surgery industry, by product.

The functional endoscopic sinus surgery market, by product, is segmented into endoscopes, surgical instruments, and navigation systems. The surgical instruments segment accounted for the largest market share in 2023. This is due to the growth in new surgical methods or techniques with improved set of instruments. The endoscopes segment to register highest CAGR during the forecast period. This is attributed to the increase in innovations in endoscopes technology such as 3D endoscopes.

In 2023, fungal sinusitis segment to dominate the Functional endoscopic sinus surgery industry, by indication

Based on indication, the functional endoscopic sinus surgery market is segmented into chronic sinusitis, recurrent sinusitis, nasal polyposis, fungal sinusitis, and other indications. The fungal sinusitis segment accounted for the largest market share in 2023. This can be attributed to the growing elderly population with weakened immune system and exposure of humans to indoor and outdoor fungal spores in the air and continuous inhalation of spores which gets deposited along the airway mucosa.

In 2023, hospitals & ASCs segment to dominate the Functional endoscopic sinus surgery industry, by end user.

Based on End user, the functional endoscopic sinus surgery market is segmented into hospitals & ASCs and specialty clinics. The hospitals & ASCs segment accounted for the largest market share in 2023. This is because ASCs manage a large volume of outpatient surgeries which gives patients a greater convenience and faster turnaround times. Also, reimbursement facilities favoring the patients will additionally aid into the market share of hospitals and ASCs.

In 2023, North America to dominate in Functional endoscopic sinus surgery industry.

The global Functional endoscopic sinus surgery market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC. North America is expected to dominate during the forecast period, primarily due to the growing availability of government funding for healthcare and R&D spending, number of patients for chronic sinusitis are on the rise, awareness programs during the World Sinus Health Awareness Month, and the presence of major players in the US.

To know about the assumptions considered for the study, download the pdf brochure

The Functional endoscopic sinus surgery market is dominated by players such as Medtronic plc (Ireland), Stryker Corporation (US), Olympus Corporation (Japan), B. Braun Melsungen Ag (Germany), and KARL STORZ (Germany).

Scope of the Functional Endoscopic Sinus Surgery Industry:

This research report categorizes the Functional endoscopic sinus surgery market to forecast revenue and analyze trends in each of the following submarkets:

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
• GCC

By Product

• Endoscopes
• Surgical Instruments
• Navigation Systems

By Procedure

• Frontal Sinus Surgery
• Ethmoid Sinus Surgery
• Maxillary Sinus Surgery
• Sphenoid Sinus Surgery
• Other Procedures

By Indication

• Chronic Sinusitis
• Recurrent Sinusitis
• Nasal Polyposis
• Fungal Sinusitis
• Other Indications

By Patient Type

• Adult Patients
• Pediatric Patient

By End User

• Hospitals & Ambulatory Surgery Centres (ASCs)
• Specialty Clinics

Recent Developments of Functional Endoscopic Sinus Surgery Industry:

• In 2024, Integra acquired Acclarent, Inc., a pioneer in ENT surgical interventions. The addition of Acclarent’s innovative product portfolio expanded the breadth of Integra’s market-leading brands and provided immediate scale and accretive growth via a dedicated sales channel.
• In 2022, Medtronic completed the acquisition of Intersect ENT, expanding the company’s comprehensive ENT portfolio with innovative products used in sinus procedures to improve postoperative outcomes and treat nasal polyps.
• In 2022, Olympus Corporation (Japan) announced FDA clearance for its CELERIS single-use sinus debrider system.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst